The GLP-1 Consumer Is Rewriting the Value of Every Bite
Why one of the biggest shifts in food isn’t about what people eat—but how they decide what’s worth eating.
In Brief
GLP-1 medications such as Ozempic, Wegovy and Mounjaro are doing more than helping people lose weight. They are changing the economics of food consumption.
As appetite declines, consumers are becoming more selective about what they eat. Calories are no longer an abundant resource to fill—they are becoming a limited budget to invest wisely.
This is beginning to reshape demand across food, beverage and restaurants, shifting value away from volume and towards nutritional quality, protein and products that feel genuinely worth consuming.
For many categories, this could become one of the most significant changes in consumer behaviour in decades.
What Is Happening
The rapid adoption of GLP-1 medications is already influencing purchasing behaviour, particularly in the United States, where usage has grown quickly. Research from PwC found that households with a GLP-1 user buy fewer sugary snacks, confectionery and alcohol, while increasing purchases of protein-rich foods, fresh produce and nutrient-dense products.
The impact extends beyond grocery baskets. Restaurant visits, portion sizes and eating occasions are also changing as consumers seek meals that provide greater nutritional value rather than simply satisfying hunger.
While Europe remains at an earlier stage of adoption, awareness is rising rapidly. As access improves over the coming years, similar shifts are likely to emerge across many European markets, although the pace and scale will vary by country.
What It Means
The most important implication is not that people are eating less. It is that they are becoming more intentional about what deserves to be eaten.
For decades, growth in many food categories has relied on larger portions, more frequent snacking and encouraging consumers to eat more. GLP-1 challenges that assumption.
When appetite becomes constrained, every bite competes harder for a place on the plate.
Products that deliver protein, satiety, nutrition or a genuinely enjoyable experience become more valuable. Those that depend primarily on habit or impulse may face increasing pressure.
This is not simply a health trend. It represents a shift in how consumers evaluate value itself.
The Original Minds Perspective
Many companies are asking whether they need a “GLP-1-friendly” product.
That is the wrong question.
GLP-1 is not creating a new customer segment. It is creating a new demand architecture.
The winners will not be those who add another label or reformulate one product. They will rethink the role their brands play when consumers become more selective, portions become smaller and nutritional usefulness matters more than sheer quantity.
Growth will increasingly come from helping consumers choose better—not consume more.
What to Consider
Leadership teams should revisit some fundamental assumptions:
Which parts of our growth strategy still depend on increasing consumption?
Which products become more valuable when every calorie must justify itself?
Are our portion sizes, menus and pack formats aligned with more intentional eating?
Where should we innovate to deliver greater nutritional value rather than greater volume?
Original Minds Conclusion
GLP-1 is often described as a pharmaceutical breakthrough.
It may prove to be an equally important commercial one.
Because when consumers become more selective, competition shifts from selling more food to creating food that is more worthy of being chosen.
The brands that understand this earliest won’t simply adapt to a new health trend.
They’ll be designing for a new era of customer choice.
--
This brief is provided by Original Minds Intelligence - our proprietary intelligence platform that scans the world for data, signals, and trends, and interprets them specifically for categories and brands, based on their specific strategy. This content is the free version of our platform.